P-Gp Inhibitors (Oral) has 2 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Relugolix, Relugolix, Estradiol Hemihydrate, And Norethindrone Acetate. Patients taking P-Gp Inhibitors (Oral) should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 2
- Major
- 2
Major (2)
- P-Gp Inhibitors (Oral) + Relugolix— Co-administration increases relugolix exposure and risk of adverse reactions. If unavoidable, separate dosing by at leas…
- P-Gp Inhibitors (Oral) + Relugolix, Estradiol Hemihydrate, And Norethindrone Acetate— Co-administration increases AUC and Cmax of relugolix, may increase risk of adverse reactions. Avoid use; if unavoidable…